We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
Read MoreHide Full Article
Phibro Animal Health (PAHC - Free Report) recently entered into an exclusive license agreement with global biotechnology company, Dyadic International, Inc. to develop and commercialize an animal health vaccine. Per the terms of the deal, Phirbo will get an exclusive license to use the Dyadic proprietary C1-cell protein production platform for the production of specific targeted antigens for the development and commercialization of a poultry vaccine for a Phibro targeted disease.
The financial terms of the deal were not disclosed.
More on the News
Dyadic works on advancing, applying, and deploying its proprietary C1-cell protein production platform for advanced performance of protein-based vaccines and therapeutics at low cost. According to Dyadic, the C1 microorganism has the potential to be further developed into a safe and efficient expression system to speed up development and improve the performance of biologic vaccines and drugs at flexible commercial scales.
Image Source: Zacks Investment Research
Per the exclusive agreement, Phirbo together with Dyadic will continue development work to find a vaccine candidate using Dyadic’s C1 cells. Further, the companies expect to continue working on developing additional animal vaccine candidates to be produced from Dyadic’s C1-cells.
According to Phirbo, following the successful animal testing of antigens produced by Dyadic's C1 expression system for a targeted disease, this agreement will help them to move into the next stage of development to produce a viable vaccine candidate.
Market Prospect
Going by an Allied Market Research report, the global animal vaccines market size is projected to reach $15,201.5 million by 2030, registering a CAGR of 5.2% from 2021 to 2030.
A Look at Phirbo's Prospering Vaccine Business
Phibro is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies. Phibro’s buyout of the assets of Israel-based developer and manufacturer of vaccines, KoVax, has widened its portfolio of aquaculture products.
In the second quarter of fiscal 2022, Phibro registered a 20% improvement in vaccine net sales, primarily driven by increased domestic and international volumes. In this regard, recently Phirbo introduced a vaccine facility in Sligo, Ireland. The company’s vaccine business is witnessing higher domestic volumes as well as increased demand in the Asia-Pacific region. Another notable buyout of the company was that of MJ Biologic’s swine vaccines in the United States.
Earlier, Phibro had stated its plans to launch the novel Lyme vaccine delivery system by 2022. Also, the company plans to return to double-digit growth in International demand driven by the success of vaccination programs in North America, Europe and in markets where countries depend on vaccines.
The latest development is going to further strengthen Phirbo’s foothold in the animal vaccine market.
Share Price Performance
In the past year, Phibro has outperformed its industry. The stock has lost 7.6% compared with the industry’s 19.8% fall.
Zacks Rank and Other Key Picks
Phirbo currently carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2, has a long-term earnings growth rate of 16.2%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 19.5%, on average.
AMN Healthcare has outperformed its industry over the past year. AMN has gained 23.8% versus the industry’s 62% decline.
Henry Schein has an estimated long-term growth rate of 11.8%. Henry Schein’s earnings surpassed estimates in the trailing four quarters, the average surprise being 21.86%. It currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein has gained 6.1% compared with the industry’s 1.7% rise over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
Phibro Animal Health (PAHC - Free Report) recently entered into an exclusive license agreement with global biotechnology company, Dyadic International, Inc. to develop and commercialize an animal health vaccine. Per the terms of the deal, Phirbo will get an exclusive license to use the Dyadic proprietary C1-cell protein production platform for the production of specific targeted antigens for the development and commercialization of a poultry vaccine for a Phibro targeted disease.
The financial terms of the deal were not disclosed.
More on the News
Dyadic works on advancing, applying, and deploying its proprietary C1-cell protein production platform for advanced performance of protein-based vaccines and therapeutics at low cost. According to Dyadic, the C1 microorganism has the potential to be further developed into a safe and efficient expression system to speed up development and improve the performance of biologic vaccines and drugs at flexible commercial scales.
Per the exclusive agreement, Phirbo together with Dyadic will continue development work to find a vaccine candidate using Dyadic’s C1 cells. Further, the companies expect to continue working on developing additional animal vaccine candidates to be produced from Dyadic’s C1-cells.
According to Phirbo, following the successful animal testing of antigens produced by Dyadic's C1 expression system for a targeted disease, this agreement will help them to move into the next stage of development to produce a viable vaccine candidate.
Market Prospect
Going by an Allied Market Research report, the global animal vaccines market size is projected to reach $15,201.5 million by 2030, registering a CAGR of 5.2% from 2021 to 2030.
A Look at Phirbo's Prospering Vaccine Business
Phibro is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies. Phibro’s buyout of the assets of Israel-based developer and manufacturer of vaccines, KoVax, has widened its portfolio of aquaculture products.
In the second quarter of fiscal 2022, Phibro registered a 20% improvement in vaccine net sales, primarily driven by increased domestic and international volumes. In this regard, recently Phirbo introduced a vaccine facility in Sligo, Ireland. The company’s vaccine business is witnessing higher domestic volumes as well as increased demand in the Asia-Pacific region. Another notable buyout of the company was that of MJ Biologic’s swine vaccines in the United States.
Earlier, Phibro had stated its plans to launch the novel Lyme vaccine delivery system by 2022. Also, the company plans to return to double-digit growth in International demand driven by the success of vaccination programs in North America, Europe and in markets where countries depend on vaccines.
The latest development is going to further strengthen Phirbo’s foothold in the animal vaccine market.
Share Price Performance
In the past year, Phibro has outperformed its industry. The stock has lost 7.6% compared with the industry’s 19.8% fall.
Zacks Rank and Other Key Picks
Phirbo currently carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2, has a long-term earnings growth rate of 16.2%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 19.5%, on average.
AMN Healthcare has outperformed its industry over the past year. AMN has gained 23.8% versus the industry’s 62% decline.
Henry Schein has an estimated long-term growth rate of 11.8%. Henry Schein’s earnings surpassed estimates in the trailing four quarters, the average surprise being 21.86%. It currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein has gained 6.1% compared with the industry’s 1.7% rise over the past year.